首页> 外国专利> VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT THERAPY AND NEOADJUVANT THERAPY, AND TREATMENT OF EARLY STAGE TUMORS

VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT THERAPY AND NEOADJUVANT THERAPY, AND TREATMENT OF EARLY STAGE TUMORS

机译：VEGF特异性拮抗剂，用于辅助治疗和新辅助治疗以及早期肿瘤的治疗

页面导航

摘要
著录项
相似文献

摘要

PROBLEM TO BE SOLVED: To provide methods of treating benign, pre-cancerous, or non-metastatic tumors.SOLUTION: The invention provides methods of treating a subject at risk of developing benign, pre-cancerous or non-metastatic tumors by administering to the subject an effective amount of a VEGF-specific antagonist, where the VEGF-specific antagonist is selected from the group consisting of a polypeptide that specifically binds to VEGF, a ribozyme, a peptibody, an antisense nucleobase oligomer, a small RNA molecule and an aptamer.SELECTED DRAWING: None

机译：要解决的问题：提供治疗良性，癌前或非转移性肿瘤的方法。解决方案：本发明提供了通过对个体给药的方法来治疗有发生良性，癌前或非转移性肿瘤风险的对象的方法。受试者治疗有效量的VEGF特异性拮抗剂，其中VEGF特异性拮抗剂选自与VEGF特异性结合的多肽，核酶，肽体，反义核碱基寡聚体，小RNA分子和适体。 .SELECTED DRAWING：无

著录项

公开/公告号JP2018052939A

专利类型
公开/公告日2018-04-05

原文格式PDF
申请/专利权人 GENENTECH INC;
展开▼

申请/专利号JP20170199344
发明设计人 FERRARA NAPOLEONE;KORSISAARI NINA;MASS ROBERT D;
展开▼

申请日2017-10-13
分类号A61K45;A61P43;A61P35;A61P35/04;A61P5;A61K39/395;A61K48;A61K38/18;A61K31/7088;A61K31/7105;A61K31/713;A61K39/39;C12N15/09;C12N15/113;C12N15/115;C07K19;C07K16;C07K14/71;C07K16/22;
国家 JP
入库时间 2022-08-21 13:11:43

相似文献

专利
外文文献
中文文献